Novel antibody composition for debulking blood and bone marrow samples from cml patients
CA 2279474 C · Owner: Stemcell Technologies Inc. · Inventors: Thomas, Terry E.; Eaves, Connie J.
Overview
Its claims, description and drawings are in the Canadian Patents Database.
Open the CIPO recordAbstract From the Canadian patent
The present invention relates to an antibody composition which contains antibodies specific for glycophorin A CD2, CD3, CD14, CD15, CD16, CD19, CD24 CD56, CD66b and IgE antigens. A negative selection process is also provided for use on blood and bone marrow samples from a patient with chronic myeloid leukemia to recover cell preparations depleted of lineage committed cells. The invention also relates to kits for carrying out this process and to the cell preparations prepared by the process.
Read the whole patent
Listed from its CIPO record in Patent Yard's archive of Canadian patents past their term. Its claims, description and drawings are in the CIPO record and on Google Patents, and the Claude kit works from them.
Why it's free to use
- Filed July 30, 1999 and granted January 4, 2011. A Canadian patent filed from October 1, 1989 lasts 20 years from filing, so its term ended July 30, 2019.
- A certificate of supplementary protection adds at most two years for a drug, so even that would have ended by July 30, 2021.
- We check Canadian rights only. A patent in its family in another country could still be in force: check its family on Google Patents.
Timeline
Timeline From CIPO dates
Sources & verification
Official CIPO records
Everything on this page comes from the CIPO record linked above. Contains information licensed under the Open Government Licence – Canada.